Why Goldman Sachs Is Waiting For Teladoc's Merger Story To Unfold
Why Goldman Sachs Is Waiting For Teladoc's Merger Story To Unfold
Teladoc Health Inc’s (NYSE: TDOC) acquisition of Livongo Health (NASDAQ: LVGO) was completed on Oct. 30 and has yet to generate impressive growth, according to Goldman Sachs.
The Teladoc Health Analyst: Robert Jones initiated coverage of Teladoc Health with a Neutral rating and $206 price target.
The Teladoc Health Thesis: The company has been a beneficiary of accelerated adoption trends amid the pandemic and appears to be on track to record around 71% revenue growth organically, Jones said in the initiation note.
“Beyond this year, the story shifts to that of a combined entity where we think legacy TDOC organic growth and synergies targets appear achievable,” the analyst said. “That said, we believe the onus for meaningful upside within legacy TDOC lies on US membership growth in Health Plan lives concurrent with PMPM (per member per month) expansion, which could pose some risk.”
Outside of the legacy Teladoc company, upside would come from synergies and legacy Livongo, which has less of a track record, according to Goldman Sachs.
TDOC Price Action: Shares of Teladoc Health were rising 2.73% to $203.06 at last check Friday. Latest Ratings for TDOC
View More Analyst Ratings for TDOC
View the Latest Analyst Ratings
Teladoc Health Inc’s (NYSE: TDOC) acquisition of Livongo Health (NASDAQ: LVGO) was completed on Oct. 30 and has yet to generate impressive growth, according to Goldman Sachs.
The Teladoc Health Analyst: Robert Jones initiated coverage of Teladoc Health with a Neutral rating and $206 price target.
特拉多克健康分析師： 羅伯特·瓊斯開始覆蓋特拉多克健康與中性評級和 $206 目標價格.
The Teladoc Health Thesis: The company has been a beneficiary of accelerated adoption trends amid the pandemic and appears to be on track to record around 71% revenue growth organically, Jones said in the initiation note.
特拉多克健康論文： Jones 在啟動說明中表示，該公司一直是大流行期間加速採用趨勢的受益者，並且似乎有機地創紀錄了 71％ 的收入增長。
“Beyond this year, the story shifts to that of a combined entity where we think legacy TDOC organic growth and synergies targets appear achievable,” the analyst said. “That said, we believe the onus for meaningful upside within legacy TDOC lies on US membership growth in Health Plan lives concurrent with PMPM (per member per month) expansion, which could pose some risk.”
分析師說：「今年以後，這個故事轉向了一個合併實體的故事，我們認為傳統的 TDOC 有機增長和協同作用目標似乎是可以實現的。」「也就是說，我們相信傳統 TDOC 中有意義上漲的責任在於美國會員健康計劃生活的增長與 PMPM（每個會員每月）的擴張同時，這可能會帶來一些風險。」
Outside of the legacy Teladoc company, upside would come from synergies and legacy Livongo, which has less of a track record, according to Goldman Sachs.
高盛稱，在傳統的 Teladoc 公司之外，優勢將來自協同效應和傳統的 Livongo，它具有較少的往績記錄。
TDOC Price Action: Shares of Teladoc Health were rising 2.73% to $203.06 at last check Friday. Latest Ratings for TDOC
TDOC 價格行動： 上週五，特拉多克健康部的股價上漲了 2.73％，至 203.06 美元。 TDOC 的最新評分
View More Analyst Ratings for TDOC
查看更多 TDOC 的分析師評級
View the Latest Analyst Ratings
查看最新的分析師評級
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧